“Mean Percent PASI Improvement With Bimekizumab in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results from Four Phase 3 3b Trials”. SKIN The Journal of Cutaneous Medicine, vol. 5, no. 6, Nov. 2021, p. s55, https://doi.org/10.25251/skin.5.supp.55.